NCT07009184

TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers.

TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers, a Phase 0/I Study.

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 19 (estimated)
• Sponsor: Radboud University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In recent years, there is increasing interest in antibodies for imaging, antibody-drug conjugates (ADC) and targeted radionuclide therapy (TRT). With these techniques, antibodies are used as a vector to deliver a cytotoxic drug or radionuclide for therapy or nuclear medicine imaging. One such antibody-based vector suitable for delivering a cytotoxic drug or radionuclide is trastuzumab, which targets HER2 that is overexpressed in cancers such as breast, gastric and gastroesophageal junction carcinomas. Unfortunately, antibodies generally have a very long circulation time (\>20-30 days) that often result in unfavorable background noise in the healthy organs in imaging or toxicity when trastuzumab is bound to a therapeutic radionuclide for radioimmunotherapy. There is thus a need to increase the speed of excretion of antibodies or release the antibody from its payload. Ideally, the clinician would like to appropriately time the elimination of radioactivity to achieve an optimal tumor to non-tumor ratio. To this aim, Tagworks Pharmaceuticals developed a new class of chemically cleavable radiolabeled conjugates that release the radiolabel on demand upon reaction with a small molecule "the trigger" (TRG001).

Detailed description

In the last decade, there was increasing interest in antibody mediated imaging, ADCs, and TRT. There are now antibodies targeting human epidermal growth factor receptor (HER2), trophoblast antigen 2 (TROP2), nectin-4, folate receptor alpha, prostate-specific membrane antigen (PSMA), among others. These drugs use antibodies as a vector to deliver a (cytotoxic) payload for imaging or therapeutic purposes. After binding to the receptor, the antibody-based therapy is internalized and introduces the drug or radionuclide to the inside of the (cancer) cell. This causes the cell to die or light up, driven by the radionuclide of choice. One of the most used antibodies in the clinic, is trastuzumab. Trastuzumab (Herceptin®) is a recombinant humanized IgG1 monoclonal antibody directed against the HER2 receptor. HER2 is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinase, and its expression is upregulated in several tumor types. HER2 is a well-defined, clinically relevant internalizing tumor target expressed at high levels in multiple different cancer types. Breast and gastric/gastroesophageal cancers have been the focus of HER2-targeted therapies, but HER2 overexpression occurs in various other malignancies of epithelial origin, such as, gastric, ovarian, bladder, salivary gland, endometrial, pancreatic, and non-small-cell lung cancer. Binding of trastuzumab to HER2-expressing cells suppresses HER2 signaling pathways, induces cell cycle arrest and mediates antibody-dependent cell-mediated cytotoxicity. Trastuzumab therapy can also be combined with chemotherapy to obtain synergistic effects, and to limit the often-observed resistance against the therapy. HER2 plays an important role in oncogenic transformation, oncogenesis, and metastatic spread of cancer. Overexpression is associated with a poor prognosis and predicts a poor response to several treatment modalities. Molecular imaging techniques substitute for invasive biopsy procedures, exhibiting an immense advantage over other available markers. Nuclear imaging using radioactively labeled trastuzumab can easily distinguish patients who are responsive to HER2-targeted therapy from patients who are primarily resistant to anti-HER2 treatment. For this purpose, trastuzumab has been functionalized with chelators such as DOTA, EDTA and deferoxamine for radiolabeling with a variety of isotopes for nuclear medicine imaging. Trastuzumab can be labeled with Indium-111 (gamma decay) or Zirconium-89 (positron decay) to assess HER2-positive disease in patients using single photon emission computed tomography (SPECT) or positron emission tomography (PET), respectively. Trastuzumab labeled with a therapeutic radionuclide could be an attractive alternative to antibody treatment or chemotherapy. A HER2-targeted antibody such as trastuzumab, labeled with therapeutic radionuclides (e.g., Lutetium-177, Yttrium-90, Actinium-225, Thorium-227, etc.) has the potential to markedly improve current HER2 targeted cancer therapy. The bystander effect (the killing of neighboring receptor-negative cancer cells by radiation crossfire) would be especially beneficial for the inherently heterogeneous metastatic tumors. In addition, contrary to standard HER2-targeted therapies, resistance to radiation is unlikely to occur. Trastuzumab-based radiotherapy has been tested in patients with trastuzumab radiolabeled with alpha-emitting Lead-212 (15) and beta-emitting Lutetium-177 and appeared to be safe. A limitation of the use of monoclonal antibodies, such as trastuzumab, as vectors for radioactivity is their slow clearance rates and thus long blood circulation time (20). Sustained circulation increases the uptake in solid tumors making them useful as vectors, but also causes significant side effects to the healthy organs such as to the bone marrow, and liver. This is particularly applicable to radionuclide therapy as the range of alpha (e.g. Actinium-225) and beta (e.g. Lutetium-177) particles ranges from \<0.4 to a few millimeters and causes serious damage to bone marrow cells resulting in severe, dose-limiting myelotoxicity for the patient, significantly limiting the therapeutic effect. This is one of the main reasons antibody-based radionuclide therapy never became a treatment for solid tumors. Moreover, the long circulation time of antibodies increases the time to image with \[111In\]In-trastuzumab SPECT or \[89Zr\]Zr-trastuzumab PET imaging to several days post tracer injection due to unfavorable background noise in the circulation and healthy organs. There is thus a need to increase the speed of excretion of antibodies or release the antibody from its (cytotoxic) payload. Ideally, the clinician would have complete temporal control over radioactivity clearance from circulation to achieve an optimal tumor to non-tumor ratio. Click-chemistry is a relatively novel chemistry method for which the Nobel prize was awarded in 2022. One method to use click-chemistry is to create click-cleavable radiolabeled conjugates. This has the potential to significantly decrease the side effects associated with radiopharmaceuticals in cancer patients, thus increasing the therapeutic effect. Tagworks Pharmaceuticals, with their TGW211 program, is proposing the use of a new class of radiolabeled monoclonal antibodies where the radionuclide is bound to the antibody (trastuzumab in the current study) via a chemically cleavable trans-cyclooctene (TCO) linker which, upon click reaction with an exogenous small molecule tetrazine, "the trigger" (TRG001), releases a fragment containing the radiolabeled chelate (\[111In\]In-DOTA fragment) instantaneously and quantitatively. Upon release in the blood circulation, the cleaved radiolabeled fragment (\[111In\]In-DOTA) is rapidly eliminated via the urine, as shown previously for unmodified chelates, thereby rapidly decreasing systemic exposure to radioactivity. Trigger-mediated cleavage occurs only extracellularly and not inside tumor cells as the trigger is cell impermeable and is administered post administration of the radiolabeled conjugate, once it has been taken up by tumor cells. In this study, we will evaluate safety and assess the time window where cleavage should be done for an optimal tumor-to-healthy organ ratio.

Conditions

• HER2 Positive Solid Tumor

Interventions

Type	Name	Description
DRUG	[111In]In-DOTA-TCO-trastuzumab	\[111In\]In-DOTA-TCO-trastuzumab is a chemically cleavable \[111In\]In-labeled trastuzumab conjugate that is administered first to the patient, it accumulates in HER2-positive tumors and internalizes in HER2-expressing tumor cells.
DRUG	Small molecule tetrazine trigger component	TRG001 is a small molecule tetrazine trigger that reacts with \[111In\]In-TGW211-DC in blood and extracellular space thus releasing a fast clearing \[111In\]In-DOTA containing fragment which is rapidly eliminated via the kidney. Because of its non-cell permeable nature, TRG001 does not reach \[111In\]In-TGW211-DC inside tumor cells and therefore the radioactivity inside tumor cells is retained by the tumor.

Timeline

• Start date: 2025-12-10
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2025-06-06
• Last updated: 2025-11-18

Locations

1 site across 1 country: Netherlands